SEPN.US Septerna, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
40.02 USD
Close of Nov 18, 2026
22.78 53.34
Market cap
USD 1.90B
P/E
-
P/B
4.63x
ROE
-15.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SEPN.US undervalued?

Graham number

The Graham number of Septerna, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Septerna, Inc. Common Stock fundamental analysis

No fundamental analysis for Septerna, Inc. Common Stock yet.

Septerna, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Septerna, Inc. Common Stock

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other …

Full company profile